{"name":"Formycon AG","slug":"formycon-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AHZANTIVE","genericName":"AFLIBERCEPT-MRBB","slug":"aflibercept-mrbb","indication":"Other","status":"marketed"},{"name":"NUFYMCO","genericName":"RANIBIZUMAB-LEYK","slug":"ranibizumab-leyk","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FYB206","genericName":"FYB206","slug":"fyb206","indication":"Neovascular (wet) age-related macular degeneration","status":"phase_3"}]}],"pipeline":[{"name":"FYB206","genericName":"FYB206","slug":"fyb206","phase":"phase_3","mechanism":"FYB206 is a biosimilar of aflibercept (Eylea) that inhibits vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to reduce abnormal blood vessel growth in the eye.","indications":["Neovascular (wet) age-related macular degeneration","Diabetic macular edema","Retinal vein occlusion"],"catalyst":""},{"name":"AHZANTIVE","genericName":"AFLIBERCEPT-MRBB","slug":"aflibercept-mrbb","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"NUFYMCO","genericName":"RANIBIZUMAB-LEYK","slug":"ranibizumab-leyk","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPdmlCUzdSYlQtUUljSE56TFExTVIwT0prR0JsRmV3OGVLV05LY1NZaTAxR05DMm1xdjdCTDd3MHRycW8tMnBnWnlIVnQxV3hQMno5dHlYT3pIQTJSaEFKUlI2VnZ3U1plNlNzcEFnVVhQUnFYb3NyNU9CUFRGNm85NWYxV2E0eVFHalBhM0N3LTRtN3paQ3NpVFp2RmdGMWNrTFFzYlYzZDFJRjAtcThRek9KSkVSRnM5VHVyengzbFYzVllXRVE?oc=5","date":"2026-03-19","type":"patent","source":"AD HOC NEWS","summary":"Regeneron Pharmaceuticals Aktie: Formycon Settlement Clears Path for Eylea Biosimilar Launch in Euro - AD HOC NEWS","headline":"Regeneron Pharmaceuticals Aktie: Formycon Settlement Clears Path for Eylea Biosimilar Launch in Euro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOUE1aaUhzeWk4QTd3RDItTm9aTlY2Zm9NbjNZMjB5R0RCOGNUeWpMc2VHMFpMZ09Yd1JsbmhoeC1VS1l1akhneHFKamxIQUNwNllENVJIbVQ0eW1BVVlIaEZ4WUZQZkVfby1ybDZFazlaTVNJanlSMG5jb0R1WS1ZS0UtNEczcU5NLXYtVEF5X2VWSFFGOWo5SGdqcklQQm1lX09nR0M5NmpYWVdMRndJM1pnYnR0aHp5elE?oc=5","date":"2026-02-22","type":"pipeline","source":"AD HOC NEWS","summary":"Formycon AG: The Quiet Biotech Bet That Could Shake Up U.S. Pharma - AD HOC NEWS","headline":"Formycon AG: The Quiet Biotech Bet That Could Shake Up U.S. Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOM1VHbWhJZVFhSmNIcFBHU0MzYzI1ZmVENU8yY1pVTjVLN3lmUW5KTDFsMi1saEE5MzBZUU5qSzdTY0dCOVZjdnFHY1EycjlMODZ5SVFQenFuRWlDLUdTcXZESl95eEdlRmxuYjBIbFE2Zk9VeFV0eWRXNEJKWGVkVU0zYWhsanNtLWJyM0NGTWs5RUJpQWY1UDBzSWt0SlVlTVpqVHRhWkhBMVFhUVRhZkRrd29zVE0?oc=5","date":"2026-02-22","type":"pipeline","source":"AD HOC NEWS","summary":"Why Formycon AG Just Landed on Wall Street’s Biotech Watchlist - AD HOC NEWS","headline":"Why Formycon AG Just Landed on Wall Street’s Biotech Watchlist","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-19","type":"patent","source":"ET Pharma","summary":"Zydus unit ties up with Formycon AG to supply biosimilar in US, Canada - ET Pharma","headline":"Zydus unit ties up with Formycon AG to supply biosimilar in US, Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOMnVjMFR2VUdCMmpsaG9OenA5N3RYb0xRM1FLVnYtZTg5QUhJenlnX252WEN3aVVMRjFVZlhDTm9JbGZBcF9tWXFfakhFZnZWcVBuNWVoNi1Ucmw2STFDc1cxRmJhUDljOWIzdUZyODRFSTFOX25hakgzMGlRYVhydXl5UDczczNlSE930gGQAUFVX3lxTFBialZ4enVKMHdaOHROVk94N2laSllJT0NSX1ZOTnB5cW93Z2FGNG4xb2RmelB5R1B6X1R6ZWJJQ0hMYzRPX2RNYl9hQk5GTVRJbDRlV0MtRzRTajA3RlFNQVM4UG02WEtWU0V1VXBjNzk1UDlKRzZlbFk0UmVzeVhpaEstTHhEYXptcl9NWnM1aQ?oc=5","date":"2025-12-10","type":"deal","source":"Express Pharma","summary":"Zydus Lifesciences signs licensing deal with Formycon - Express Pharma","headline":"Zydus Lifesciences signs licensing deal with Formycon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPdWNON2FlemlwZ0U3a3ZrWEdIUWRuQ0hGQWljREhMVU1PYTNTbWlaM2dibjBUTFc3ZTR6U1JZVmMzUlp6eFBqbGE3Y204UEpJMnNPZ0FYRU1iUGs4RVhiRjZ4X2E5Si1CMUdkeHdMZHc5X192VElHb2hDX0l0N2FwZ2JPTFdFMGIwQUVSVHFBOGVGTmlkTENraEE3a3VuSDZzQkRMc21LQzc?oc=5","date":"2025-12-10","type":"deal","source":"Contract Pharma","summary":"Zydus & Formycon Partner for Keytruda Biosimilar in US & Canada - Contract Pharma","headline":"Zydus & Formycon Partner for Keytruda Biosimilar in US & Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNVm9PYzJWYzdROXNZcENBLTNPMy1QUFZmQmoxQ05LbjREbm5LdFBCczhWYS1vdVExU3pmV0JJNC1NZlVMRkEtY2ItRlh3WEhQaGk4X1hYaW9XNUZnNTdHMjRyZm1sWEQ2c0pMRjZWYTVzWmtveW5KRWFmRWxDcUJmRGMyd0gwUnZ1Nm8xXzdYSEhGVkJ2Z2d2MlF4dkd5U1loRkpyclk3M2dqOGJxVVpaNmVDeTV1dTViYkNPZWk0c1dIYU1ka1U1Zmx0bGl3UExWeTVxRTAxbXRURHNkLUM3aEluYWYwanJUa1Qza2xWMEdhUUpFQkRWR2RZLTNQbWFmeFJNZXF0bTFrYnk4WE9hYXFn?oc=5","date":"2025-12-04","type":"deal","source":"PR Newswire","summary":"Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region - PR Newswire","headline":"Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the ME","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOejZleXNyUUhzelU1SFRBY19fWXZWUGFQMlk1czNScHprVFJBQWxya0wxVHVjQUVmSkljSjNpcWd3YWQwMzVrVkVVSUxralZlNTdWUThZZlBjVTRoMi1TMEdEZFVpVkVkOHhONElXakJKdENNa2dFa055OUI5VHh6Q2lGcW9RMFlsRi1HR0N2UEVRUGFUaU5lYWFGdlRsNlVEWlNkbk5yU2JOTHE1WThscnFjQUNtd2diQlFB?oc=5","date":"2025-12-02","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Formycon signs new aflibercept biosimilar pacts and launches ranivisio in Europe - Generics and Biosimilars Initiative","headline":"Formycon signs new aflibercept biosimilar pacts and launches ranivisio in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOUXFsZVZLeDcyZmE1S3ZBZzE1Sl9MWjB0T1BySEdtSUp6aG0wTVpVc2RMTU0taTZFYWxYSGpKT1lIMWI3VUxhaW1MQ0MxREFXMHpKM0l5bXZ1S3IzVmlvQ0k5RXEyTWVjaENtZ2dsdW14MFhtalp5WDFxOG14U1BTYmVGR0VFZ3JZMFR3NG5zeEdvZ3g2eDMxV1hvUEkyQnJHcXpiOXRrR1NvM0g3R0JwN1djMnpEMGJSVFBYUHBSdXItRk81cGRhYWUwcktNRDFuaXJCVXNrUVI1UkhfVjQxVHA2OU1BYTROWlc0QmZQY1FwRlZReW5nelNMQ0pROFBqVHdkRTFxM0ZrMHBFcUE?oc=5","date":"2025-10-20","type":"patent","source":"Business Wire","summary":"Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar - Business Wire","headline":"Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxOYXlkdEo2V0paM3JES1JJM2V3d3p3YS1Sc0lsSS1HaG00R3VCOHA4TkdEUlFMeHJ1QUhsckpPSE5FZUk3RFNyT2pqa1VFWmhYXzN3WFlCT2NzV0EtWkNnb1NTLWRfb1pmVVpzdlZTZXM1OEJyOVJkQkRhZ2I0UVhINlNldi1IQTg4cjRaNm94ZE9BbFRwWjNRTWlZQUh3RjVWeG45REI3OVFXY05CLXI5X2tSMjMtMWRzcUd5c2xUYktsWVdSY0toa2ZaY1NhREFwMC0zTWtodHMxb3JndjktNDZhdEFRUk50TXFrOWxWci1MMFdzSTlMd2dJZlpiRGpzOW1RVjA5bw?oc=5","date":"2025-06-05","type":"patent","source":"Ophthalmology Times Europe","summary":"Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG) - Ophthalmology Times Europe","headline":"Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOVDR2TVlKeDhPVmNFNEh6RElzZ3ZFeTc2bGp3ZEQ5d1JKWDZkSGZocWJ6SGZPc1JLSlQ4NTltNGd1U09fQ0FWdDd0SXRSTFgwVFRLWUl5dzFMbTJuZkxwZ1RpZkx5VlVMaWhpcEZtQTM0eVJuTkZOc2lxY2JIR0hvZXpZM0E4YlEwZjI3WGVibzM4V3BSLWVocElzZnpLbUptQUFraklmdlg5c0Q3eWtTM1lIYmhQT1I4dzZfTDd4Nms3azRLblVoN2U3U1ctWmdMc3BISHdHM19NeFllTkkxRWIzcmhpLUx5aldj?oc=5","date":"2025-04-08","type":"patent","source":"dlapiper.com","summary":"Distribution of generic pharmaceuticals through third parties is not enough to avoid personal jurisdiction - dlapiper.com","headline":"Distribution of generic pharmaceuticals through third parties is not enough to avoid personal jurisdiction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQXy1jRUp1X1Y3eEJBVXVOaXo5amJQVzhwQnBoMkxieVNvUzQ0T2VwbmFOSmRlLUh2OVFTYTVLRFpzMV9xZE1mQUFsQlgwSEtvQV9xcmFsNWJmOUZ1QjBDUDVUX004MVluT285dlVzMW1sRHNYUG1qelB0b0g1SnIzcUsxZEVZLXRDR0FJdzExaUswVTFRTGNFY2l3ZVBEZm8xaWZQa0tQaEw4cXdLak5iVHppVHh0dDVnNjYtdWx5MUd3b3ZzSnpxWFRYa3pRcmRaX3BLRHlWWkhmV2Y4M0E?oc=5","date":"2025-01-13","type":"deal","source":"Ophthalmology Times Europe","summary":"Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept) - Ophthalmology Times Europe","headline":"Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar afliber","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":1,"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}